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REOPRO REMOVAL DURING CARDIOPULMONARY BYPASS USING A HEMOCONCENTRATOR
Michael Poullis, FRCS, Richard Manning, BSc, Dorian Haskard, FRCP, and Kenneth Taylor, FRCS, London, United Kingdom
ReoPro (abciximab) is the Fab fragment of a monoclonal
antibody raised in mice against platelet glycoprotein IIb/IIIa
complex (Gp11b-IIIa) that is present on the surface of
platelets. Administration of this monoclonal antibody frag-
ment results in almost total inhibition of platelet aggregation.1
ReoPro has proved to be a major advance in the field of inter-
ventional cardiology, especially during coronary angioplasty
and coronary stenting. Unfortunately, some patients treated
with ReoPro remain unstable or develop unstable angina after
intervention. Cardiac surgery is then dangerous because of the
excessive bleeding that may occur in patients who have
received ReoPro.2,3 Since the bleeding that can occur can be
so catastrophic that patients have died as a result, patients may
be turned down by cardiac surgeons, or not referred at all.
Manufacturer guidelines (Eli Lilly and Company, Ltd) rec-
ommend that any patient undergoing surgery after the admin-
istration of ReoPro should receive 10 units of platelets to
absorb free ReoPro in the plasma. The transfusion of this large
number of platelets is not only costly but also associated with
significant side effects. At some smaller surgical units, suffi-
cient platelets may simply not be available at short notice.
Scattered case reports of successful cardiac surgery after the
administration of ReoPro are in the literature, but none of the
papers note that platelet function tests were performed to con-
firm that the dose of ReoPro administered to their patients was
sufficient to significantly alter platelet aggregation.
Because ReoPro has a molecular weight of 50 kd, we spec-
ulated that it might be possible to remove free ReoPro from
the circulation by using a hemoconcentrator during car-
diopulmonary bypass. This would, of course, be unlikely to
reverse the effect of ReoPro on the patient’s existing platelets,
but it would change the purpose of the platelet replacement
from one of primarily absorbing free antibody to one of pro-
viding adequate hemostasis. This would have enormous
implications to the current practice in cardiac surgery with
regard to patients who have received ReoPro,4,5 in that sig-
nificantly fewer platelets would be required.
Methods. A standard cardiopulmonary circuit was estab-
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lished by using the Stockert cardiopulmonary bypass
machine (Stockert Instrumente GMBH, Munich, Germany)
(n = 3). Pressure was monitored with a Tycos gauge (Tycos
Instruments, Inc, Arden, NC), and nonpulsatile flow was
used. A Bard hemoconcentrator type HC70 (Bard Vascular
Systems Division, Haverhill, Mass) was used in line to re-
move the ReoPro. An Avecor cardiovascular cardiotomy/
venous reservoir with filter was used (Avecor Cardiovascular,
Inc, Plymouth, Minn). The pump prime, 1.5 L total, consist-
ed of normal saline solution (n = 1) or packed red cells and
normal saline solution (starting hemoglobin value 8.0 g/dL, n
= 2), with added ReoPro such that the final concentration was
10 m g/L. One hour of in vitro bypass was performed, with cir-
culating prime sampled before, 5 minutes after initiation of in
vitro bypass, and then at 15-minute intervals up to 60 min-
utes. The in vitro bypass was performed with a mean line
pressure of 70 mm Hg, which equated to a hemoconcentrator
flow of approximately 1.1 L/min. The experiment was con-
ducted at a temperature of 28oC.
ReoPro levels were assayed by means of platelet function
tests on freshly prepared platelets, compared with a standard
curve. A standard laboratory protocol was adhered to, using
ADP for platelet stimulation and a Clandon Aggrecorder II
(YSI Ltd, Farnborough, UK) for measuring aggregation.
ADP has previously been shown to return the most repro-
ducible platelet function tests after ReoPro administration.
The normal dose of ReoPro administered to patients is 0.15
to 0.3 mg/kg body weight, which corresponds to 10.5 to 21
mg in a 70-kg patient. Since the average blood volume of a
70-kg adult is 2.5 L, and the minimum pump prime during
cardiopulmonary bypass is 1.5 L, the effective circulating
volume in patients connected to the bypass circuit is 4 L,
resulting in a final ReoPro concentration of between 2.625
and 5.25 m g/L. We used a pump prime concentration of 10
m g/L because the samples were diluted 2-fold in the platelet
aggregation assay, thus resulting in the usual pharmacologic
concentration.
Results. In initial experiments we established the condi-
tions for measuring platelet aggregation by using an aggre-
gometer. As shown in Fig 1, A, optimal platelet aggregation
was observed by using ADP at a concentration of 5.0
m mol/mL, and this concentration was therefore adopted for
further studies. Furthermore, a dose-response titration of
ReoPro showed inhibition of platelet aggregation between
1.25 and 10 m g/L, with complete inhibition at the highest
concentration (Fig 1, B).
To determine whether hemoconcentration could affect the
functional activity of ReoPro, we mixed platelets in PRP 1:1
with the priming solution at various times after initiation of
simulated bypass. As shown in Fig 1, C, effective inhibition
of platelet aggregation in response to 5.0 m mol/mL ADP was
lost by 30 minutes. Similar results were obtained by using
10.0 m mol/mL ADP (not shown).
Discussion. The results we have obtained, using a highly
sensitive and clinically relevant assay, prove the principle that
ReoPro can be removed from a cardiopulmonary bypass circuit
by using a hemoconcentrator. Patients who undergo urgent car-
diac surgery after ReoPro administration constitute a very high
risk group. Removal of the ReoPro may result in a substantial
decreased risk of bleeding during and after cardiac surgery.
The main use for our method of ReoPro elimination is
obviously during cardiopulmonary bypass, but there could be
other uses. For post–interventional cardiology patients who
Fig 1. A, Platelet aggregation over time, with ADP concen-
trations from 0.625 to 5 µmol/mL. B, Platelet aggregation
over time, with ReoPro concentration from 1.25 to 10 µg/L.
C, Platelet aggregation over time, with time after initiation of
bypass (ADP 5 µmol/mL final concentration). It can be seen
that effective inhibition of platelet aggregation, due to
RepPro removal, in response to 5.0 µmol/mL ADP is lost by
30 minutes. The data shown above were obtained from exper-
iments using saline solution as the pump prime. The results
obtained by using blood as the pump prime were identical.
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have received ReoPro and who subsequently have intracra-
nial, retroperitoneal, or gastrointestinal bleeding, manage-
ment becomes difficult; there is a natural hesitancy to reverse
anticoagulation by provision of clotting factors in a patient
who needs anticoagulation from the cardiac point of view.
Because hemofiltration is easily carried out at the bedside,
this could provide an avenue of treatment in a difficult and
potentially hazardous situation.
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